Karyopharm Targets Clinical Milestones Despite Wider Losses: SENTRY and EC-042 Pave Way for 2026
2025 Sees Steady Commercial Foundation Amid Broader Losses
Karyopharm Therapeutics (NASDAQ:KPTI) delivered its fourth quarter and full-year 2025 results, revealing the company’s resilience in a competitive oncology landscape. Full-year total revenue remained stable at $146.07 million, while U.S. XPOVIO® (selinexor) net product revenue reached $114.86 million—up slightly from the previous year. Despite a 24% improvement in loss from operations, Karyopharm reported a net loss of $196.04 million, reflecting higher interest expense and a significant loss on the extinguishment of debt due to 2025 financing rounds.
SENTRY and EC-042 Clinical Results Poised as Major 2026 Catalysts
The company is entering a defining phase with two major Phase 3 clinical programs approaching top-line readouts:
- Myelofibrosis – SENTRY Trial: Top-line results are expected in March 2026, testing selinexor in combination with ruxolitinib (vs. standard ruxolitinib regimen) in JAK inhibitor-naïve patients. Early blinded aggregate safety data suggest potential improvements in adverse events compared to prior studies.
- Endometrial Cancer – XPORT-EC-042 Trial: Data from the event-driven global trial are on track for mid-2026. This trial targets TP53 wild-type advanced or recurrent endometrial cancer, an area with limited existing therapies.
Karyopharm’s CEO highlighted these milestones as potential inflection points for the company, with the SENTRY trial representing a chance to launch the first combination therapy for myelofibrosis and EC-042 targeting a large unmet need in gynecologic oncology.
XPOVIO Revenue Stable, Global Reach Expands
U.S. net product revenue from XPOVIO® rose 1.8% year-over-year, totaling $114.86 million in 2025. The fourth quarter showed continued demand in the multiple myeloma market, with community practices contributing about 60% of annual net product revenue. International patient access improved thanks to favorable reimbursement and regulatory decisions in Spain, China, and additional countries—with selinexor now approved in more than 50 countries overall.
Operational Efficiency Improves as Expenses Fall
Karyopharm slashed research and development (R&D) and selling, general & administrative (SG&A) costs in both the fourth quarter and full year. R&D spending fell to $125.62 million (from $143.23 million) and SG&A to $105.21 million (from $115.44 million) for 2025, largely due to lower personnel costs and cost-reduction initiatives.
| Financial Metric | Q4 2025 | Q4 2024 | Full Year 2025 | Full Year 2024 |
|---|---|---|---|---|
| Net Product Revenue | $32.09M | $29.25M | $114.86M | $112.81M |
| License & Other Revenue | $1.99M | $1.29M | $31.21M | $32.43M |
| Total Revenue | $34.08M | $30.54M | $146.07M | $145.24M |
| Loss from Operations | $(17.84M) | $(31.28M) | $(90.71M) | $(119.44M) |
| Net Loss | $(102.20M) | $(30.78M) | $(196.04M) | $(76.42M) |
Guidance Points to Stability: Revenue and Cash Runway
For 2026, Karyopharm projects total revenue of $130–$150 million, with U.S. XPOVIO net product revenue targeted at $115–$130 million. R&D and SG&A expenses are guided lower, expected to total $230–$245 million. The company’s $64.1 million cash position (as of December 31, 2025) is estimated to fund operating plans into Q2 2026, as management continues to focus on clinical advancement and commercial cost control.
Key Takeaways for Investors: Clinical Visibility with Measured Execution
2026 is shaping up as a pivotal year for Karyopharm. With milestone readouts from the SENTRY myelofibrosis and EC-042 endometrial cancer trials, investors will be watching results that could drive the next phase of growth or portfolio expansion. Meanwhile, the operational discipline and cost optimization displayed in 2025 position the company to absorb clinical risk while maintaining a stable commercial platform.
As always, upcoming trial results and additional regulatory milestones will likely dictate the longer-term trajectory for Karyopharm, making it an important year for stakeholders to monitor both clinical and financial developments.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI